The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-02
DOI
10.1038/srep30749
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
- (2016) Carolina Gutiérrez et al. AIDS
- Histone Deacetylase Inhibitor Romidepsin InhibitsDe NovoHIV-1 Infections
- (2015) Kasper L. Jønsson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients
- (2015) Adam M. Spivak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
- (2015) Gregory M. Laird et al. JOURNAL OF CLINICAL INVESTIGATION
- Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir
- (2015) Julia A. Sung et al. JOURNAL OF INFECTIOUS DISEASES
- Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
- (2015) Rikke Olesen et al. JOURNAL OF VIROLOGY
- Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
- (2015) Kai Deng et al. NATURE
- Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
- (2015) Marta Martínez-Bonet et al. Scientific Reports
- The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
- (2015) Ole S. Søgaard et al. PLoS Pathogens
- Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ–NF-κB signaling
- (2014) Guochun Jiang et al. AIDS
- A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
- (2014) Sunil Sharma et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1
- (2014) Grant R. Campbell et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
- (2014) N. M. Archin et al. JOURNAL OF INFECTIOUS DISEASES
- A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
- (2014) E. R. Plimack et al. ONCOLOGIST
- Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
- (2014) Julian H. Elliott et al. PLoS Pathogens
- Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
- (2014) Richard Brad Jones et al. PLoS Pathogens
- Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
- (2014) Datsen George Wei et al. PLoS Pathogens
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
- (2014) Thomas A Rasmussen et al. Lancet HIV
- Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
- (2013) Marian Iwamoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo
- (2013) E. J. Beans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reactivation of latent HIV by histone deacetylase inhibitors
- (2013) Kotaro Shirakawa et al. TRENDS IN MICROBIOLOGY
- An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients
- (2013) Celsa A. Spina et al. PLoS Pathogens
- Histone/protein deacetylases and T-cell immune responses
- (2012) T. Akimova et al. BLOOD
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- (2012) Sally Clive et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
- (2012) K.-T. Lin et al. CLINICAL CANCER RESEARCH
- Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
- (2012) Liang Shan et al. IMMUNITY
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
- (2012) N. M. Archin et al. NATURE
- Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
- (2012) Brian A. DeChristopher et al. Nature Chemistry
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells
- (2011) Suha Saleh et al. Retrovirology
- Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals
- (2010) Ard van Sighem et al. AIDS
- Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
- (2010) Anthony P. Lam et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Bryostatin-1, a Naturally Occurring Antineoplastic Agent, Acts as a Toll-like Receptor 4 (TLR-4) Ligand and Induces Unique Cytokines and Chemokines in Dendritic Cells
- (2010) Maria Eugenia Ariza et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
- (2010) J. C. Burnett et al. JOURNAL OF VIROLOGY
- Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
- (2010) Rajeev Mehla et al. PLoS One
- Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid
- (2009) Nancie M. Archin et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
- (2009) Paul M. Barr et al. AMERICAN JOURNAL OF HEMATOLOGY
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
- (2009) Anna C. Pavlick et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
- (2009) S. Woo et al. CLINICAL CANCER RESEARCH
- Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
- (2009) Sophie Reuse et al. PLoS One
- Neuroprotective versus tumorigenic protein kinase C activators
- (2009) T.J. Nelson et al. TRENDS IN BIOCHEMICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More